% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • alternatepatel alternatepatel Jun 25, 2013 4:26 PM Flag

    Amylin (AMLN) rejected 22$/share offer by BMS in March 2012

    Amylin (AMLN) rejected unsolicited 22$/share offer by BMS in March 2012 according to bloomberg,
    they explored a sale process and got sold for 31$/share on 30th june 2012.

    Learning: The amylin story tells us that unsolicited bids are generally and obviously far away from the best ones, so as the bidder can come up with revised higher bids if initial low ball bids are rejected.

    Now, if we apply the learning to Optimer, which rejected 20$/share offer by Cubist according to Reuters(reported on May 15), we should be getting 20/share AT LEAST, or more..

    that makes a 50% upside from taday's close of 13.36

    any thoughts?

    SortNewest  |  Oldest  |  Most Replied Expand all replies